Evidence map›Paper›PMID 35433460›Full record

ArticleFrontiers in oncology2022

Evaluation Exploration of Atlas-Based and Deep Learning-Based Automatic Contouring for Nasopharyngeal Carcinoma.

Jinyuan Wang, Zhaocai Chen, Cungeng Yang, Baolin Qu, Lin Ma, Wenjun Fan, Qichao Zhou, Qingzeng Zheng, Shouping Xu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinyuan WangDepartment of Radiation Oncology, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Zhaocai ChenManteia Technologies Co., Ltd., Xiamen, China.
Cungeng YangManteia Technologies Co., Ltd., Xiamen, China.
Baolin QuDepartment of Radiation Oncology, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Lin MaDepartment of Radiation Oncology, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Wenjun FanDepartment of Radiation Oncology, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Qichao ZhouManteia Technologies Co., Ltd., Xiamen, China.
Qingzeng ZhengDepartment of Radiation Oncology, Beijing Geriatric Hospital, Beijing, China.
Shouping XuDepartment of Radiation Oncology, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The purpose of this study was to evaluate and explore the difference between an atlas-based and deep learning (DL)-based auto-segmentation scheme for organs at risk (OARs) of nasopharyngeal carcinoma cases to provide valuable help for clinical practice. Methods: 120 nasopharyngeal carcinoma cases were established in the MIM Maestro (atlas) database and trained by a DL-based model (AccuContour Results: The results of the three methods were almost similar for the brainstem and eyes. For inner ears and temporomandibular joints, the results of the pre-built DL-based model are the worst, as well as the results of atlas-based auto-segmentation for the lens. For the segmentation of optic nerves, the trained DL-based model shows the best performance (p < 0.05). For the contouring of the oral cavity, the DSC value of V Conclusion: The trained DL-based segmentation performs significantly better than atlas-based segmentation for nasopharyngeal carcinoma, especially for the OARs with small volumes. Although some delineation results still need further modification, auto-segmentation methods improve the work efficiency and provide a level of help for clinical work.

Indexed as

atlasauto-segmentationdeep learning (DL)nasopharyngeal carcinoma (NPC)organs at risk (OARs)training

Identifiers

PMID35433460
PMCPMC9008357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.